228 results
6-K
BLU
Bellus Health Inc
7 Jun 07
Current report (foreign)
12:00am
PUBLISHED IN THE NEW ENGLAND JOURNAL OF
MEDICINE SHOWS IMPORTANT BENEFITS OF EPRODISATE (KIACTA™)
TREATMENT FOR PATIENTS WITH AMYLOID A (AA) AMYLOIDOSIS … ) demonstrate that this product candidate offers important clinical benefits to patients by reducing the progression of AA amyloidosis-associated renal
6-K
BLU
Bellus Health Inc
4 Nov 03
Current report (foreign)
12:00am
DEMONSTRATES COGNITIVE BENEFITS IN PATIENTS
WITH ALZHEIMER'S DISEASE
MONTREAL NOVEMBER 4, 2003 -- Neurochem Inc. (NASDAQ … ).
The data has revealed that patients with mild AD(4) (n=6) showed the greatest
benefits from Alzhemed(TM) as compared to patients with moderate AD patients(5
6-K
BLU
Bellus Health Inc
3 Nov 06
Current report (foreign)
12:00am
be found at http://www.neurology.org under
the "Expedited E-pub" section.
"This paper demonstrates the potential benefits of ALZHEMED(TM)," said Dr … to confer short-term symptomatic benefits.
- - There was a gradual decline in the psychometric scores for subjects
remaining in the study over
6-K
BLU
Bellus Health Inc
22 Jun 06
Current report (foreign)
12:00am
, Groningen, the Netherlands, and an investigator for the Phase II/III
clinical trial.
"The benefits of Fibrillex(TM) to patients during this clinical trial … trials may not provide definitive results regarding safety,
tolerability or therapeutic benefits. Even if all the endpoints sought in the
clinical trials
6-K
BLU
Bellus Health Inc
24 Apr 06
Current report (foreign)
12:00am
for
tramiprosate (Alzhemed(TM)), involving mild-to-moderate AD patients, continues
to show clinically significant benefits on cognitive and global … regarding the results of
clinical trials may not provide definitive results regarding safety,
tolerability or therapeutic benefits. Even if all the endpoints
F-10
EX-4.2
4qb0jok1
3 Sep 19
Registration of securities (Canada)
7:53am
F-10
EX-4.2
ljga4u6s52wrmn2y kcl
20 Dec 19
Registration of securities (Canada)
4:03pm
40-F
EX-99.2
nia ibmm0
23 Feb 22
Annual report (Canada)
5:20pm
6-K
EX-99.2
98nxcwojcq 0mrhpc
12 Nov 20
Condensed Consolidated Interim Financial Statements of
4:09pm
40-F
EX-99.2
cchawlix
27 Feb 20
Annual report (Canada)
5:13pm
6-K
g0i1focc
8 Nov 07
Current report (foreign)
12:00am
6-K
EX-99.1
nul xkbinknhl2
12 May 23
BELLUS Health Reports First Quarter 2023 Financial Results and Business Highlights
4:02pm
6-K
EX-99.1
5dmszuw4kid1 3m01p
8 Sep 20
BELLUS Health Announces Design for its Phase 2b Trial with BLU-5937 in Refractory Chronic Cough
7:00am
6-K
EX-99.2
xam7fvaug nnb
10 May 21
Condensed Consolidated Interim Financial Statements of
4:48pm
6-K
EX-99.2
ahg3mnre9rhv
11 Aug 21
Condensed Consolidated Interim Financial Statements of
4:43pm
40-F
EX-99.2
fpcgo5nthmxu1vq
25 Feb 21
Annual report (Canada)
4:58pm
6-K
EX-99.2
vbe1qh3z9g30fdw
10 Nov 21
Condensed Consolidated Interim Financial Statements of
4:42pm
6-K
EX-99.2
fdyryoaq
14 May 20
Condensed Consolidated Interim Financial Statements of
5:12pm
6-K
EX-99.2
qslzl8vw1wjji3y7qi7
13 Aug 20
Condensed Consolidated Interim Financial Statements of
4:01pm
6-K
EX-99.2
86x zgano6
12 May 23
Condensed Consolidated Interim Financial Statements of
4:32pm